-
Views
-
Cite
Cite
Endocrinology & Metabolism News April 2005, The Journal of Clinical Endocrinology & Metabolism, Volume 90, Issue 4, 1 April 2005, Page 16a, https://doi.org/10.1210/jcem.90.4.9995
- Share Icon Share
Extract
Endocrine Discovery
In 28 women with treated hypothyroidism, addition of a daily 5 μg T3 dose with a 25 μg per day reduction in T4 in a blinded crossover trial produced no change in quality-of-life and psychometric tests, but more than one half of patients still preferred combination treatment, which suppressed TSH to the low range in 10 patients.
(
Ann Int Med
[March 15] 2005;142:412–424)Lifestyle and metformin delayed development of type 2 diabetes by 11 and 3 years, respectively, and reduced the incidence of diabetes by 20% and 8%, respectively, compared with a placebo intervention. Survival was improved by 0.5 and 0.2 years. The cost was much less for lifestyle than metformin intervention, $1,100 versus $31,300 per quality-adjusted life-year.
(
Ann Int Med
[Mar. 1, 2005] 142:323)Lactic acidosis did not occur in more than 7,000 metformin-treated diabetes patients who were prospectively followed for 12 months in the Comparative Outcomes Study of Metformin Intervention Versus Conventional (COSMIC) Approach Study.
(
Diabetes Care
[Mar. 2005] 28:539)Issue Section:
The Endocrine Society
You do not currently have access to this article.